Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

The beta‐site amyloid precursor protein cleaving enzyme‐1 (BACE‐1) initiates the
generation of amyloid‐β (Aβ), and the amyloid cascade leading to amyloid plaque …

Alzheimer's disease (AD) is a neurodegenerative disorder linked to protein misfolding and
aggregation. AD is pathologically characterized by senile plaques formed by extracellular …

Alzheimer's disease (AD) is one of the most common causes of dementia. Its pathogenesis
is characterized by the aggregation of the amyloid-β (Aβ) protein in senile plaques and the …

Introduction Alzheimer's disease (AD) pathology, including the accumulation of amyloid beta
(Aβ) species and tau pathology, begins decades before the onset of cognitive impairment …

Introduction: The amyloid hypothesis of Alzheimer's disease (AD) affirms that brain
accumulation of amyloid-β (Aβ) oligomers and soluble aggregates represent the major …

Alzheimer's disease (AD) is associated with marked atrophy of the cerebral cortex and
accumulation of amyloid plaques and neurofibrillary tangles. Amyloid plaques are formed by …

Abstract Introduction Multidomain intervention for Alzheimer's disease (AD) risk reduction is
an emerging therapeutic paradigm. Methods Patients were prescribed individually tailored …

Abstract Introduction Recruitment for Alzheimer's disease (AD) prevention research studies
is challenging because of lack of awareness among cognitively healthy adults coupled with …